Exit Wockhardt, prefer Sun Pharma: Shahina Mukadam

Shahina Mukadam, Independent Market Expert told CNBC-TV18, "I would suggest a switch from Wockhardt to maybe Sun Pharmaceutical Industries.
Wockhardt is rallying because their management has offered their Waluj, Aurangabad plant for reinspection, but by the time the whole process is completed will be another six months. And the other facilities are also having problems with US Food and Drug Administration (FDA)."

"The US markets, Europe markets are very important for the company which is facing certain issues. So I would suggest to switches to Sun, book some profit because Sun now, there is possibility of an earlier resolution of its Halol plant and there, they have also recently got a new approval for an new drug application (NDA). So these small products will go a long way in adding both revenues as well as profitability for Sun over the next one year," she added.